# Rural prioritization may increase the impact of COVID-19 vaccines in Sub-Saharan Africa due to ongoing internal migration: A modeling study

Prashanth Selvaraj<sup>a</sup>, Bradley G. Wagner<sup>a</sup>, Dennis L. Chao<sup>a</sup>, Maïna L'Azou Jackson<sup>b</sup>, J. Gabrielle Breugelmans<sup>c</sup>, Nicholas Jackson<sup>c</sup>, Stewart T. Chang<sup>a</sup>

<sup>a</sup>Institute for Disease Modeling, Bill and Melinda Gates Foundation, Seattle, Washington, USA <sup>b</sup>Coalition for Epidemic Preparedness and Innovations, Oslo, Norway <sup>c</sup>Coalition for Epidemic Preparedness and Innovations, London, UK

#### Abstract

How COVID-19 vaccine is distributed within low- and middle-income countries has received little attention outside of equity or logistical concerns but may ultimately affect campaign impact in terms of infections, severe cases, or deaths averted. In this study we examined whether subnational (urban-rural) prioritization may affect the cumulative two-year impact on disease transmission and burden of a vaccination campaign using an agent-based model of COVID-19 in a representative Sub-Saharan Africa country setting. We simulated a range of vaccination strategies that differed by urban-rural prioritization, age group prioritization, timing of introduction, and final coverage level. Urban prioritization averted more infections in only a narrow set of scenarios, when internal migration rates were low and vaccination was started by day 30 of an outbreak. Rural prioritization was the optimal strategy for all other scenarios, e.g., with higher internal migration rates or later start dates, due to the presence of a large immunological naive rural popula-

Preprint submitted to Lancet Global Health

June 19, 2021

tion. Among other factors, timing of the vaccination campaign was important to determining maximum impact, and delays as short as 30 days prevented larger campaigns from having the same impact as smaller campaigns that began earlier. The optimal age group for prioritization depended on choice of metric, as prioritizing older adults consistently averted more deaths across all of the scenarios. While guidelines exist for these latter factors, urban-rural allocation is an orthogonal factor that we predict to affect impact and warrants consideration as countries plan the scale-up of their vaccination campaigns.

Keywords: COVID-19, vaccination, urban/rural transmission, serology, sub-Saharan Africa, vaccination impact, low and middle income countries

#### Introduction

- 2 COVID-19 has presented every country with a challenge to formulate
- a strategy to protect its population, initially with non-pharmaceutical in-
- 4 terventions (NPI)/public health and safety measures (PHSM) and more re-
- 5 cently vaccination. As of June 2021, the World Health Organization (WHO)
- 6 has granted Emergency Use Listing to five vaccines [1], though supplies are
- 7 expected to be limited, particularly in low- and middle-income countries
- 8 (LMIC). The COVID-19 Vaccines Global Access (COVAX) Advance Market
- 9 Commitment (AMC) is expected to be the primary mechanism by which
- $_{10}$  most of 92 eligible LMICs procure COVID-19 vaccines, beginning with 3%
- $_{
  m HI}$  population coverage for health care workers (HCW) and increasing to 20%
- population coverage for the elderly and adults with comorbidities [2]. Previ-
- ous modeling studies have indicated that prioritizing elderly adults for vac-

cination would yield the largest reductions in mortality [3, 4] given the steep gradient of mortality observed with age in China, Europe, and other countries [5, 6]. Meanwhile, HCW have been prioritized to preserve health system capacity [2]. How countries should allocate vaccines subnationally has received little attention outside of equity or logistical considerations. While the WHO requires countries to submit national deployment and vaccination plans (ND-VPs) [7] prior to receiving vaccines from COVAX [8], WHO guidance on developing NDVPs mentions geography only in the context of ensuring equitable access. In particular the guidance encourages countries to give special consideration to "those living in informal settlements or urban slums... populations in conflict settings or those affected by humanitarian emergencies, and other hard-to-reach population groups" but does not explore the epidemiological impact of such policy decisions [7]. Likewise, WHO guidance on logistics mentions "remote areas" but only with respect to the ultra-low temperatures required to store certain vaccines and the need for special devices such as thermal shippers with dry ice [9]. These documents highlight the challenges that rural areas (and some urban areas) are expected to face during COVID-19 vaccination campaigns and suggest that the default may be to overlook these areas or distribute vaccine to these areas at a slower pace. In this study we ask whether urban or rural prioritization of COVID-19 vaccines may also affect the impact of the vaccination campaign on disease burden. Using an agent-based model set in a representative Sub-Saharan African (SSA) setting, we examine the possible impact on transmission and

- disease burden of campaigns prioritizing urban or rural areas to receive vac-
- 40 cine first, while also accounting for other factors such as age group prior-
- 41 itization, variable dates of vaccine introduction, and final vaccine coverage
- 42 levels.

#### 43 Results

Ongoing migration generates multiple peaks in COVID-19 incidence at the

45 country level

To explore possible COVID-19 trajectories in SSA, we created an agentbased model of the spread of COVID-19 in a SSA-like country setting where the population was split between urban and rural areas. The population was assumed to be immunologically naive, and NPI/PHSM policies were simulated as dynamic changes in transmission. Infections were seeded in the urban node and allowed to spread to rural nodes through internal urban-rural migration (Figure 1).

In the baseline scenario, moderate transmission and ongoing migration ( $R_0 = 2.4$ , migration = 20 000 daily trips per million individuals, dtpmi) resulted in separate incidence peaks in urban and rural areas which aggregated to give two peaks at the country level (Figure 1, middle column, middle row). Cases rose quickly in urban areas and more gradually in rural areas with urban and rural peaks separated by approximately four months. After two years, a majority of the overall population ( $58\% \pm 2\%$ ) had been infected at some point (Figure 2). A larger fraction of the urban population was ever infected (81% cumulative urban infections vs. 48% cumulative rural infections), but rural infections outnumbered urban infections due to the larger




Figure 1: Daily COVID-19 incidence with varying transmission and migration in an archetypal SSA country setting. Urban and rural curves show new cases per day out of a population of 400 000 individuals split 40% urban and 60% rural. Peak percentages represent cumulative incidence as a percentage of the respective sub-population on the date when the highest incidence in each sub-population occurs indicated by the dashed vertical line. Time in days since first imported case. Low, medium, and high migration = 2000, 20 000, and 200 000 dtpmi, respectively.

- 63 rural population (Figure 2).
- Using the baseline scenario as reference, we examined the effects of trans-
- mission and migration separately on the epidemic characteristics (Figure 1).




Figure 2: Cumulative COVID-19 incidence with varying transmission and migration in an archetypal SSA country. Urban and rural curves show percentage ever infected out of a population of 400 000 individuals split 40% urban and 60% rural. Peak percentages represent cumulative incidence as a percentage of the respective sub-population on the date when the highest incidence in each sub-population occurs indicated by the dashed vertical line. Time in days since first imported case. Low, medium, and high migration = 2000, 20 000, and 200 000 dtpmi, respectively.

- Increasing the transmission rate (from  $R_0 = 2.0$  to 2.8) while holding mi-
- gration constant shortened the time between urban and rural peaks (e.g.,

from 287 to 92 days when migration = 20~000 dtpmi, Figure 1). This also resulted in a proportional increase in cumulative incidence as expected (Figure 2; however, other qualitative features such as the number of peaks at the country level remained unchanged (Figure 1). By comparison, increasing the internal migration rate while holding transmission constant resulted in qualitative changes to the incidence curve including the number of peaks at the country level (Figure 1). At medium rates of migration (migration = 20 000 dtpmi), separate urban and rural peaks were apparent at the country level with any level of transmission (Figure 1). In this scenario, approximately equal numbers of cases came from urban and rural areas (Figure 2). At low rates of migration (migration = 2000 dtpmi), the outbreak was predominantly urban, with urban areas contributing the majority of cases (Figure 2). Rural incidence failed to increase appreciably but instead contributed to a long tail of declining incidence at the country level (Figure 1). Conversely, at high rates of migration (migration = 200 000 dtpmi), a predominantly rural outbreak was observed, with rural areas contributing the majority of cases (Figure 2). Incidence increased in both urban and rural areas but continued increasing in rural areas even after starting to decline in urban areas (Figure 1). Therefore, both low and high migration rates tended to produce single-peak outbreaks, while intermediate migration rates resulted in multiple peaks, marking the transition between between predominantly urban and rural outbreaks. At extreme values of transmission and migration, the model demonstrated two contrasting outbreak scenarios. A more contained, primarily urban outbreak was generated when transmission and migration rates were low  $(R_0 =$ 

```
2.0 and migration = 2000 dtpmi); cumulative incidence was 62\% and 5\% in
    urban and rural areas, respectively, and 22\% \pm 2\% at the country level (Fig-
    ure 2). A less contained, widespread outbreak was generated when transmis-
    sion and migration rates were high (R_0 = 2.8 and migration = 200 000 dtpmi);
    cumulative incidence was 78% and 63% in urban and rural areas, respectively,
    and 68\% \pm 2\% at the country level (Figure 2). This range of cumulative in-
    cidence was consistent with seroprevalence rates in SSA [10, 11, 12, 13, 14].
    Increasing coverage has a limited capacity to compensate for delays in COVID-
100
    19 vaccine introduction
101
       To examine the effect of COVID-19 vaccination policies on population-
102
    level impact, we simulated roll-out strategies that differed in several respects:
    age prioritization (i.e., older or younger adults first), timing (start day) of vac-
104
    cine introduction, final vaccine coverage level, and spatial prioritization (i.e.,
105
    urban or rural areas first). Vaccines were assumed to be either acquisition-
106
    blocking (preventing most infection after exposure) or disease-blocking (al-
107
    lowing infection and limited transmission but preventing most disease). Im-
    pact was evaluated on the basis of cumulative infections, severe cases, and
109
    deaths averted after two years compared to a counterfactual baseline scenario
110
   of moderate transmission and ongoing migration (R_0 = 2.4, migration = 20
111
    000 dtpmi).
112
       We first asked what effect age prioritization and timing of introduction
113
    might have on vaccination impact (Figure 3). To simplify the analysis, we
114
    fixed vaccine coverage at 50% and distributed vaccine to both urban and
115
    rural areas with equal priority. We found that the optimal age prioritiza-
116
    tion strategy depended on the choice of impact metric. Prioritizing younger
```

adults to receive an acquisition-blocking vaccine averted more infections than prioritizing older adults or random distribution by age (e.g., 15%±3% versus 13%±2% and 7%±2%, respectively, when introduced at day 60, Figure 3, left column, top row), consistent with the large proportion of younger adults in SSA populations ([15]) and degree of contact that occurs within this age group ([16]). With a disease-blocking vaccine, prioritizing younger adults continued to be more effective in averting infections than prioritizing older adults, but the relative differences were reduced (Figure 3, left column, bottom row).




Figure 3: Vaccination impact by age prioritization and timing of vaccine introduction. Age groups for prioritization were as follows: "old first" = beginning with adults age 70 years or older; "young first" = beginning with adults age 15–49 years; "random" = without prioritization (i.e., all ages have equal priority).

By comparison, prioritizing older adults was consistently more effective at averting severe cases or deaths than prioritizing younger adults or random distribution by age. For an acquisition-blocking vaccine, prioritizing older adults averted approximately twice as many deaths as prioritizing younger adults, regardless of date of introduction (Figure 3, right column, top row). These differences were greater in magnitude for a disease-blocking vaccine (Figure 3, right column, bottom row). Regardless of impact metrics, delays in vaccine introduction reduced but did not negate the absolute differences in impact between age prioritization strategies (Figure 3).

We then asked whether higher coverage levels could compensate for a 136 later date of introduction. In this case, we assumed priority would go to 137 older adults based on the deaths averted as a metric (Figure 4) and WHO 138 fair allocation guidelines [2]. Final coverage levels were varied between 20% 139 and 80% representing COVAX targets [2] and an optimistic scenario with ad-140 ditional vaccine procurement, respectively. Regardless of metric (infections, 141 severe cases, or deaths averted) or start day of vaccination (30-180 days after first case), increasing vaccination coverage also increased the impact (Figure 4). 144

The maximum possible impact for any given coverage level diminished rapidly with delays in the start of vaccination (Figure 4). An optimistic campaign with 80% coverage of an acquisition-blocking vaccine averted 16% of infections when introduced on day 30 but only 2% of infections when introduced on day 180. The impact of vaccination at other coverage levels was similarly diminished by delays in introduction (Figure 4). As a result, higher coverage levels were necessary for a campaign started later to have the same impact as a campaign started earlier with lower coverage levels. In certain cases, the gain from starting vaccination earlier could not be matched by delayed vaccination, even with very high final coverage levels. For example,

to avert the same number of deaths (32% of baseline deaths) as a campaign started on day 30 with 30% coverage, a campaign started on day 90 would need to attain 80% coverage (Figure 4, right column, top row). However, campaigns started on day 30 with  $\geq$ 60% coverage resulted in levels of impact ( $\geq$ 44% of baseline deaths averted) that could not be achieved by campaigns started later, regardless of coverage level (examined up to 80% coverage) (Figure 4, right column, top row).

#### Lost time does not make up for greater coverage later




Figure 4: Vaccination campaign impacts by final coverage level and timing of vaccine introduction. Percentage reductions are shown for the respective cumulative indicator (infections, severe cases, or deaths) with respect to the baseline scenario without intervention.

Trends with respect to age prioritization, timing of introduction, and final coverage levels were robust to choice of baseline scenarios, including changing the level of transmission or ongoing migration (Supplementary Information).

Rural prioritization optimizes vaccination in the presence of ongoing migration

Finally we asked to what extent spatial (urban or rural) prioritization 167 could affect the impact of a COVID-19 vaccination campaign in an archety-168 pal SSA setting. We again assumed that priority would be given to older 169 adults but that within each age tier, those in the prioritized spatial setting 170 would be vaccinated first. For example, for rural prioritization, we assumed 171 vaccine would go to rural individuals 70+ years, then urban 70+ years, rural 60-69 years, and so on. We also varied final coverage levels (20%, 50%, 173 or 80%), start dates of introduction (30, 90, or 180 days), and type of vac-174 cine (acquisition- or disease-blocking). For our counterfactual, we assumed 175 a baseline of moderate transmission and ongoing migration ( $R_0 = 2.4$ , mi-176 gration = 20 000 dtpmi) or the extremes of a more confined or less confined outbreak ( $R_0 = 2.0$ , migration = 2000 dtpmi or  $R_0 = 2.8$ , migration = 200 178 000 trips dtpmi, respectively) (cf. Figures 1, 2). 179

For the majority of vaccination scenarios, we found that rural priori-180 tization would avert more infections, severe cases, and deaths than urban prioritization (Figure 5). Urban prioritization achieved greater impact for 182 a small set of conditions: when the outbreak was largely confined to urban 183 areas (with low transmission and low migration) and vaccination was started 184 early in the outbreak (by day 30) (Figure 5, left column). For all other sce-185 narios, including those with higher transmission or migration, or campaigns started at later dates, rural prioritization resulted in greater impact (Fig-187 ure 5, center and right columns). These differences were most pronounced 188 when impact was measured by infections averted. For other metrics such as severe cases (Figure 5, rows 2 and 5), the differences between urban and rural prioritization tended to be modest but still significant, e.g., with medium transmission and migration ( $R_0 = 2.4$ , migration = 20 000 dtpmi, medium migration). This was attributable to the prolonged spread of the epidemic in such scenarios (Figure 1) as well as our assumption that age groups would be given priority over spatial distribution such that in all scenarios in Figure 5, older age groups were vaccinated first.

The acquisition-blocking vaccine had a higher impact on transmission 197 than the disease-blocking vaccine, particularly when impact was measured 198 by infections averted. However, differences in impact between the two vac-199 cine types were strongly dependent on transmission trajectories over time, 200 coverage, and the start time of vaccine roll-out. In the low migration and low 201 transmission scenario ( $R_0 = 2.0$ , migration = 2000 dtpmi), the two vaccines 202 were largely similar. For example, for campaigns prioritizing urban areas 203 started on day 30, both vaccines had negligible effects on infections averted 204 with 20% final coverage. These differences increased to 7% of infections (10%) 205 and 3% with acquisition- and disease-blocking, respectively) with 80% final 206 coverage (Figure 5, left column) and decreased with delays in the start date of vaccine roll-out. When transmission and migration were both higher ( $R_0$ 208 = 2.4, migration = 20 000 dtpmi, medium migration), the epidemic per-209 sisted longer (Figure 1), and larger magnitude differences between vaccine 210 types were observed. For campaigns prioritizing rural areas started on day 211 30, the difference between vaccine types was 3\% of infections with 20\% final coverage and 15% of infections with 80% final coverage (Figure 5, middle column). These modest absolute differences in impact were attributable to




Figure 5: Vaccination campaign impact on infections, severe cases and deaths by spatial (urban-rural) prioritization. Bars indicate mean reduction in respective cumulative indicator, and error bars indicate standard error.

the slow roll-out of vaccine over a 12-month period, particularly during the first 9 months when <50% of the vaccine will have been distributed [17].

The differences between acquisition-blocking and disease-blocking vac-217 cines were reduced when impact was measured by severe cases and deaths (Figure 5). The acquisition-blocking vaccine resulted in 2-4% more severe 219 cases averted than the disease-blocking vaccine across transmission scenarios 220 due to the reduction in transmission (Figure 5, rows 2 and 5). However, the 221 difference between vaccine types was negligible for deaths averted (Figure 5, 222 rows 3 and 6). This was attributable to our assumption that both vaccines provide protection against severe disease and deaths and that age groups 224 would be given priority over spatial distribution. 225

In all three transmission scenarios in Figure 5 as well as the remaining scenarios (Supplemental Information), increased NPI/PHSM that also reduced migration maximized the impact of vaccination campaigns.

# <sup>29</sup> Discussion

By applying an agent-based model with discrete individuals, we found that ongoing urban-rural migration has the potential to extend COVID-19 outbreaks in a SSA-like setting. With either low or high internal migration rates, our model predicted that a single incidence peak at the country level would follow introduction, predominated by cases in urban and rural areas, respectively. However, with intermediate migration rates, our model predicted that an initial predominantly urban outbreak would be followed by a second rural outbreak, resulting in two peaks and extending the duration of the outbreak.

Each of these migration scenarios was in turn associated with a different 239 optimal vaccination strategy. When migration rates were low (whether due 240 to geography, NPI/PHSM, or other causes) and if the vaccine could be rolled out quickly, the optimal strategy was to target urban areas, preventing the predominantly urban outbreak. However, with higher rates of urban-rural 243 migration, targeting rural areas resulted in greater impact and was the opti-244 mal strategy, consistent with the largely rural population in SSA. Delays in 245 vaccination also resulted in rural prioritization becoming the optimal strategy, as urban areas experienced outbreaks faster than rural areas and a larger proportion of the population resided in rural areas. 248

The differences in impact between urban and rural prioritization strate-249 gies warrant consideration as countries begin vaccinating their populations in 250 larger numbers. We are not aware of any NDVPs (such as made available on 251 the WHO COVID-19 Partners Platform [18]) that distinguish between urban 252 and rural areas, though a few countries such as Mexico are reportedly prior-253 itizing rural areas [19]. While WHO guidance on subnational allocation has 254 been limited to equity or logistical considerations, possible effects on impact 255 were not explored [7, 9, 8]. If resources are not intentionally directed to rural areas, urban allocation is likely to be the default strategy throughout SSA 257 and other LMIC. For example, Ameyaw et al. examined Demographic and 258 Health Survey data from 2010-2018 and found that children in urban areas 259 were fully vaccinated at higher rates than their rural counterparts (by 53% 260 to 41%, respectively) [20]. While we do not consider other mitigating factors such as the ease of distribution in urban areas, the question of whether to vaccinate a larger, immunologically naive rural population or a smaller, previously exposed urban population encapsulates what we expect is a dilemma
that countries may be facing in the near future. In this study we found that
vaccinating rural areas may have benefits beyond equity.

Spatial prioritization complemented other strategies such as prioritizing 267 older adults, as recommended by official WHO guidance [2]. Prioritizing 268 younger adults with a vaccine effective against acquisition reduced the over-269 all number of infections, but prioritizing older adults more greatly reduced 270 severe cases and deaths. The inability of prioritizing younger age groups to 271 prevent as many severe cases and deaths as prioritizing older age groups was 272 ultimately due to the anticipated slow roll-out of vaccine. This in turn reflects 273 current projections which foresee a 12-month roll-out to reach 20% coverage 274 that is back-loaded; approximately 50% of the available doses is expected to 275 come in the last three months [17]. This pace, even assuming coverage rates >20\%, make it difficult to achieve herd immunity fast enough to prevent infections, severe cases, and deaths in older adults without direct targeting. These results are consistent with other recent models on COVID-19 vaccine impact [21, 4, 3]. 280

Our model also supports the position that countries should begin their vaccination campaigns as soon as possible. Campaigns that started later had a limited capacity to make up for the delay in vaccination, even when higher coverage levels were assumed. In many scenarios, larger campaigns that started started later resulted in more deaths than smaller campaigns that started earlier. This supports the urgency to direct vaccine to SSA as quickly as possible, a position espoused by COVAX [22], the African Union [23], and civil society [24].

One question that we did not address directly is which scenario currently 289 best fits each country in SSA: which have high or low ongoing internal mi-290 gration, or high or low transmission? Because both of these parameters are 291 abstracted in the model, we propose that a careful epidemiological assessment would be needed for each country to measure the outcome of ongoing 293 migration if present: a high cumulative incidence in rural areas compared to 294 urban areas. For example, this might be accomplished through serosurveys 295 as in Niger State in Nigeria [12] or through genomic surveillance to track 296 variants as in South Africa [25], Nigeria [26], and Kenya [27]. Both studies 297 showed that infections spread from urban centers to rural areas and that ru-298 ral areas were slower to see increases in incidence, consistent with a degree of 299 restricted migration. Both countries and others in SSA may still have large 300 immunologically naive populations in rural areas. 301

Our model was informed by a mix of historical data but plausibly rep-302 resents a future scenario. For example, while almost all SSA countries saw 303 initial outbreaks during the year 2020, the example of Manaus, Brazil demon-304 strates how new variants may evade even high levels of existing immunity 305 [28]. In such situations, future outbreaks may continue to resemble new outbreaks, leading to successive almost-memoryless incidence peaks. In addition, the vaccine roll-out in SSA has been limited thus far, making our 308 assumption reasonable that future vaccinations will essentially be starting 309 anew. As of June 2021, the Africa CDC reported that less than 2\% of mem-310 ber country populations received at least one dose of any vaccine and less than 0.5% have been fully vaccinated [29]. Therefore, variants and low existing vaccine-induced immunity suggest our model and other outbreak-type 4 models will continue to have relevance.

Our study had several limitations. As an abstraction of a SSA country 315 setting, our model represents an average in many respects: demographics (ages, contact patterns, urban-rural localization), COVID-19 response (as 317 tracked by Oxford CGRT [30]), and a generic urban-seeded outbreak. This 318 abstraction represents a trade-off that allowed us to focus on outbreak scenar-319 ios that may be applicable to many countries, though not precisely calibrated 320 to any particular country. Our model also had several parameters that were 321 abstractions of physical processes and not precisely matched to data. For ex-322 ample, internal migration did not correspond to a particular indicator such as 323 mobile phone-based movement but represents an aggregate of this and other 324 factors contributing to net migration [31]. We also made several simplifying 325 assumptions on COVID-19 immunity and vaccines such as previous infection leading to perfect immunity and optimistic vaccine characteristics such as 327 those based on mRNA vaccines [32, 33], as well as no opportunity for rein-328 fection. We also did not explicitly account for any particular SARS-CoV-2 320 variants. However, by spanning a range of transmission rates, we accounted 330 for increased infectiousness expected of new variants. In this case, our se-331 lected vaccine efficacy rates may represent best-case scenarios, with variants further reducing the impact on infections, severe cases, and deaths. 333

In sum, our model supports the position that countries should consider spatial prioritization among other factors when planning how to distribute COVID-19 vaccine, particularly those in SSA where vaccine supplies are expected to be limited. These countries have an ongoing opportunity to adapt their strategy and if necessary set up an infrastructure that allows vaccine

to be prioritized to maximize impact.

### Methods

41 Model structure and demographics

COVID-19 transmission dynamics were simulated using EMOD, a soft-342 ware platform for agent/individual-based epidemiological modeling of infectious diseases [34]. EMOD was used to represent an archetypal country in sub-Saharan Africa (SSA) [35] through demographics (age pyramid and urban-rural population distribution), contact structure, and mobility pat-346 terns. Demographics were represented by taking the mean of each five year 347 age bin from the population pyramids in the SSA region [36]. The urban-rural 348 distribution of the population was obtained from published UN estimates, and the mean was taken for all countries in SSA [15] (Figure 10). Contact 350 structures for the same set of age bins and countries in urban and rural set-351 tings were obtained from Prem et al. [16]. These matrices were available for 352 home, school, workplace, and community settings, and a simple mean was 353 taken across SSA countries. To obtain the total contact matrices, we multi-354 plied the NPI policy effect from the Oxford COVID-19 Government Response 355 Tracker described below and then summed all four settings together. Mobil-356 ity patterns represented the within-country movement of people as described 357 below. Baseline parameter values are provided in Table 1 except for contact 358 matrices which are provided in Supplemental Methods. 359 Individuals were created at model initialization and assigned (a) an age to 360

Individuals were created at model initialization and assigned (a) an age to match the desired age distribution and (b) a node representing either urban or rural settings to match the desired urban-rural population distribution.

In total the model contained 200 nodes with node<sub>1</sub> representing an urban setting and node<sub>2.,200</sub> representing rural settings with the same population 364 sizes at initialization (Figure 6). The urban node accounted for 40% of 365 the total population, while the rural nodes accounted for the remaining 60%. This node structure was chosen to represent an SSA country having a capital 367 city serving as the main hub of international traffic and rural areas whose 368 residents travel to the capital city and other rural towns. Migration between 369 urban and rural nodes and between rural nodes was represented as a change 370 in the node assignment of individuals. The probability of a change in node was calculated as the product of a base rate and the population sizes of 372 each pair of nodes, i.e., using a gravity-based model (Figure 6). The base 373 migration rate was not known a priori, so a range of values were evaluated 374 spanning several orders of magnitude (Table 1). This rate and other rates in the model were implemented as exponentially distributed waiting times between random events. Other demographic processes such as births, non-377 disease deaths, and migration to other countries were assumed negligible on the timescale of the model. The model was run for a simulated 2-year (730 379 day) duration. 380

#### 381 COVID-19 epidemiology in the model

We represented COVID-19 outbreaks where an infected case was introduced into a population that did not have pre-existing immunity (as happened in year 2020) or where a new SARS-CoV-2 variant might be introduced that completely evades existing immunity. Individuals (agents) were assumed to be in one of the following states: susceptible, infected, or removed (recovered or dead). Infected individuals were seeded in the urban




Figure 6: Model schematic showing sample node and migration. Infected individuals were seeded in the urban node and infection spread to rural nodes via urban-rural migration.

Symbol	Parameter	Units	Baseline value	Range	Reference
$S_{t=0}$	Initial susceptible prop	Percent	99.9	NA	NA
$I_{t=0}$	Initial infected prop	Percent	0.1	NA	NA
$R_{t=0}$	Initial removed prop	Percent	0	NA	NA
$R_0$	Base reproduction number	New infections / infected indiv	2.4	2.0 - 2.8	NA
$NPI_t$	NPI intensity effect	Unitless multiplier	Varies	0 - 100	[30]
$\gamma$	(Avg infec duration) <sup>-1</sup>	Days <sup>-1</sup>	14-1	NA	[37]
$VE_S$	Vax effic vs infec	Scalar	0.95	{0.95, 0}	[32, 33]
$VE_I$	Vax effic vs trans	Scalar	0.3	{0, 0.7}	NA
$VE_P$	Vax effic vs progr	Scalar	1.0	{0, 1.0}	[32, 33]
$P_{vac}$	Final vax coverage	Percent	50	{20, 50, 80}	[2]
$p_{rural}$	Rural pop	Percent	60	NA	[15]
b	Baseline migration	Probability / time step	20 000 dtpmi	20 - 200 000 dtpmi	NA
$N_{tot}$	Model agents	Integer	$4 \times 10^{5}$	NA	NA
$n_{rural}$	Rural nodes	Integer	199	NA	NA
$n_{urban}$	Urban nodes	Integer	1	NA	NA
t	Time step	Days	1	NA	NA

Table 1: Model parameters

node at multiple time points (Table 1) during the first 60 days after which no additional importations were assumed to occur due to suspension of air

travel. Susceptible individuals became infected at a rate proportional to a baseline rate of transmission  $R_0I(t)/c_{i,j}\gamma$  where  $R_0$  represents the base repro-391 duction number of COVID-19 from literature (Table 1), I(t) the number of 392 infected individuals in the same node,  $c_{i,j}$  the mean contact rate of individ-393 uals of age groups i and j, and  $\gamma =$  mean infectious duration in the model. 394  $c_{i,j}$  was obtained from the age- and location-dependent contact rates from 395 Prem et al. [16] across settings and countries in SSA. Infected individuals 396 transitioned to the removed state with the sum rate of recovery and death, i.e., the inverse of the total infectious duration. Removed individuals did 398 not return to the susceptible state which was equivalent to (a) births and 399 deaths being negligible on the timescale of the model and (b) recovered in-400 dividuals having perfect immunity that did not wane on the timescale of the 401 model. Individual-level behaviors were also simulated to a limited extent: 10% of infected individuals were assumed to self-isolate which reduced their 403 contributions to transmission in their respective node by 80%. 404

## 405 Country-level events and policies in the model

To represent typical country-level policies to outbreaks, we included a quantification of NPI/PHSM policy strengths implemented in SSA since early 2020. We obtained data from the Oxford COVID-19 Government Response Tracker (OxCGRT) Containment and Health Index which is the average of 14 sub-indexed indicators ranging between 0 and 100 where each sub-index rates a specific type of policy on each day [30]. Dates in OxCGRT were re-scaled to the date since first case reported to the WHO ([38], Table 2). To derive a mean value for SSA, we used the mean  $NPI_t$  across countries in SSA for each date since respective first case 7.  $(1 - NPI_t/100)$  was used

as a contact rate multiplier for work and community settings. The school settings was assumed to be closed (i.e., with  $NPI_t = 100$ ) for 135 days after first reported case then reopened with the same contact rate multiplier as work and community settings. The home setting was assumed to have 418 increased contact rates by 25% (i.e., with  $NPI_t = -25$ )). After the last day 419 of available  $NPI_t$  data, work, school, and community settings were assumed 420 to be opened to 75% of pre-COVID levels (i.e., with  $NPI_t = 25$ ) to simulate 421 near-complete reopening in most SSA countries. We used the same multiplier 422  $(1 - NPI_t/100)$  on migration between all spatial nodes in the simulation to account for changes in migration because of NPI policies.

Calendar day	Epidemic day $(t)$	Event or policy
15	-60	Importations begin
75	0	Earliest policies (assumed first reported case)
90	15	Importations stop
105 - 255	30 - 180	Vaccinations begin
210	135	Schools reopen

Table 2: Summary of events and policy implementation dates in model. Calendar day 0 = January 1, 2020

## Vaccination in the model

428

- COVID-19 vaccines in the model were represented as protecting individ-426 uals by one of the following mechanisms: 427
- 1. Acquisition-blocking: preventing susceptible individuals from becoming infected (called efficacy against susceptibility,  $VE_S$  in the biostatistical 429 literature [39]) 430
- 2. Transmission-blocking: preventing shedding of infectious particles after 431 infection (efficacy against infectiousness,  $VE_I$ , in the literature [39]) 432




Figure 7: NPI policies as scored by OxCGRT for SSA countries

433

434

435

436

437

439

3. Disease-blocking: preventing individuals from developing symptomatic disease (efficacy against symptomatic illness,  $VE_P$ , in the literature [39])

We assumed that vaccines would be highly efficacious and comparable to the Pfizer/BioNTech or Moderna mRNA vaccines with >90% clinical trial efficacy and effectiveness [32, 33]. We also made the simplifying assumption that observed efficacy  $VE_{obs}$  was entirely attributable to either  $VE_S$  or  $VE_I$  (see 1). That is, for an acquisition-blocking vaccine, we assumed  $VE_S = VE_{obs}$  and  $VE_P = 1$  resulting in all of the vaccinated individuals being protected from disease progression despite infection. For a disease-blocking

vaccine, we assumed  $VE_I = VE_{obs}$ ,  $VE_P = 1$ , again resulting in all of the vaccinated individuals being protected from disease progression, even if infected. Thus all vaccines, regardless of type, were assumed to prevent severe disease and mortality. In the case of vaccines with lower efficacy, the preventive effect on severe disease and deaths is also assumed to decrease 447 linearly. Finally, as our focus was on factors under the control of country 448 policymakers, we did not explicitly model SARS-CoV-2 variants or their 449 impact on vaccine efficacy. However, we expect that variants would have the 450 net effect of reducing impact similar to reduced coverage levels. 451 Vaccine availability followed the COVAX projections of vaccine supply 452 available from GAVI [17]. Briefly these projections assume vaccine will be-453 come increasingly available over a period of 12 months until reaching a final 454 vaccination population coverage of  $P_{vac} = 20\%$  or greater (Table 1). 455 Different age prioritization schemes were assumed to be available: oldest 456 first (in order: 70+ years, 60-69, 50-59, and 15-49), youngest first (in order: 457 15-49 years, 50-59, 60-69, and 70+), or random (all ages at the same time) 458 (Figure 9). Likewise, different spatial allocation schemes were assumed vi-459 able: urban first, rural first, or random (equal priority to urban and rural areas) (Figure 9). Under random spatial prioritization, vaccine was distributed 461 to urban and rural nodes at a rate proportional to population size, e.g., at 1\% 462 coverage, both 1% of the urban population and 1% of the rural population 463 would be covered. In the case of both age and spatial prioritization, age was assumed to take precedence before spatial (urban, rural) setting.

vaccine, each dose was assumed to confer an increasing level of protection

At the individual (agent) level, if an individual was selected to receive a

465

466

until the level of protection specified by  $VE_S$ ,  $VE_I$ , or  $VE_P$  was attained (Figure 8). This profile was chosen to reflect the Moderna scheduling of 469 28 days between first and second doses [33]. Individual efficacy (regardless 470 of type) was assumed to begin at 0% on day 0 and increase linearly until reaching 80% of final efficacy on day 10. This was maintained until day 472 28 when a second dose was assumed administered, then efficacy increased 473 linearly until final efficacy was reached on day 35. We assumed that all 474 individuals selected for vaccination would receive both vaccine doses and 475 that individual protection would not wane on the timescale of the model. Vaccination scenarios in the model used the same random number draws as baseline scenarios so that the individual- and population-level characteristics 478 were the same until the vaccination campaign began. Each scenario was 479 run with 40 realizations to derive mean and standard deviation of summary statistics. 481




Figure 8: Ramp-up of protective effect within a vaccinated individual in the model




Figure 9: Vaccine allocation scenarios by spatial prioritization, age group, and month

## Parameter ranges for scenarios

We evaluated vaccine distribution scenarios over a range of base transmission intensities represented by  $R_0$  and migration rates. In the scenarios presented,  $R_0$  varied between 2.0 to 2.8. Migration varied from a scenario where simulated agents make 2000 daily trips per million individuals (dtpmi) under unmitigated (no NPI/PHSM) conditions to a high migration scenario where 200 000 trips are completed each day.

With respect to vaccine distribution, we evaluated different final coverage 489 levels and vaccine distribution start times in addition to different age and 490 spatial prioritization strategies in urban and rural areas. Coverage levels were 491 varied from 20%-80% of the total population, while start times were varied 492 between 30-180 days after the first case. While the same start times were used 493 across different transmission scenarios, the number of infected individuals 494 varied depending on transmission intensity preceding the start of vaccine 495 distribution. Vaccine distribution start times could thus be considered a 496 proxy for different levels of population immunity at the start of a vaccination 497 campaign. 498

Contact structure, age pyramid, and government response tracker data were available for 37 countries in sub-Saharan Africa, and all 37 countries (shown in Figure 10) were used to develop a representative SSA country. A full list of countries is available upon request.

#### 3 Acknowledgments

The authors would like to thank Jonathan Bloedow and Christopher Lorton from the Bill and Melinda Gates Foundation for software support and
Bob Small and Amol Chaudhari from the Coalition for Epidemic Preparedness Innovations and the WHO SAGE Working Group on Covid-19 Vaccines
for informative discussions. This publication is based on research conducted
by the Institute for Disease Modeling at the Bill and Melinda Gates Foundation. No external funding was involved.




Figure 10: Sub-Saharan African countries that were aggregated to form a representative country.

# Supporting information

- Supplementary figures: Supplementary\_figures.pdf.
- All code to reproduce the modeling results are available on Github or by request to the authors.

# Author contributions statement

P.S., B.W., D.L.C., and S.C. conceived the model scenarios. P.S. designed and implemented the model and generated model outputs. S.C. and P.S.

wrote the manuscript. All authors reviewed the manuscript.

#### References

- [1] World Health Organization. Status of COVID-19 Vac-520 within WHO EUL/PQevaluation process. Geneva: cines 521 World Health Organization; 2021. Available from: https: 522 //extranet.who.int/pqweb/key-resources/documents/ 523 status-covid-19-vaccines-within-who-eulpq-evaluation-process. 524
- [2] Fair allocation mechanism for COVID-19 vaccines 525 COVAX 2021. through the Facility; Available 526 from: https://www.who.int/publications/m/item/ 527 fair-allocation-mechanism-for-covid-19-vaccines-through-the-covax-facility. 528
- [3] Bubar KM, Reinholt K, Kissler SM, Lipsitch M, Cobey S, Grad YH, et al. Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. Science. 2021 Feb 26;371(6532):916–921. doi:10.1126/science.abe6959.
- [4] Hogan AB, Winskill P, Watson OJ, Walker PGT, Whittaker C, Baguelin M, et al. Within-country age-based prioritisation, global allocation, and public health impact of a vaccine against SARS-CoV-2: A mathematical modelling analysis. Vaccine. 2021 May 21;39(22):2995–3006. doi:10.1016/j.vaccine.2021.04.002.
- <sup>538</sup> [5] Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: a model-

- based analysis. The Lancet Infectious Diseases. 2020 Jun;20(6):669–677. doi:10.1016/S1473-3099(20)30243-7.
- [6] Levin AT, Hanage WP, Owusu-Boaitey N, Cochran KB, Walsh SP,
   Meyerowitz-Katz G. Assessing the age specificity of infection fatality
   rates for COVID-19: systematic review, meta-analysis, and public policy
   implications. European Journal of Epidemiology. 2020 Dec;35(12):1123–
   1138. doi:10.1007/s10654-020-00698-1.
- [7] Guidance on developing a national deployment and vaccination plan for COVID-19 vaccines. Geneva: World Health Organization; 2021. Available from: https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-Vaccine\_deployment-2020.1.
- [8] COVID-19 national deployment and vaccination plan: Submission 551 and review process, 29 January 2021. Geneva: World Health 552 2021. Organization; Available from: https://www.who.int/ 553 publications-detail-redirect/WHO-2019-nCoV-NDVP-country\_ 554 plans-2021.1. 555
- [9] COVID-19 vaccination: supply and logistics guidance. 556 Geneva: World Health Organization; 2021. Available from: 557 https://www.who.int/publications-detail-redirect/ 558 who-2019-ncov-vaccine-deployment-logistics-2021-1. 559
- [10] Milleliri JM, Coulibaly D, Nyobe B, Rey JL, Lamontagne F, Hocqueloux
   L, et al. SARS-CoV-2 Infection in Ivory Coast: A Serosurveillance Sur-

- vey among Gold Mine Workers. American Journal of Tropical Medicine and Hygiene. 2021;104(5). doi:10.4269/ajtmh.21-0081.
- [11] Milleliri JM, Coulibaly D, Nyobe B, Rey JL, Lamontagne F, Hocqueloux L, et al. Seroprevalence of anti-SARS-CoV-2 IgG anti-bodies among truck drivers and assistants in Kenya. medRxiv. 2021;doi:10.1101/2021.02.12.21251294v1.
- [12] Majiya H, Aliyu-Paiko M, Balogu V, Musa D, Salihu I, Kawu A,
  et al. Seroprevalence of COVID-19 in Niger State. medRxiv.
  2020;doi:10.1101/2020.08.04.20168112.
- [13] Mukwege D, Byabene AK, Akonkwa EM, Dahma H, Dauby N,
   Buhendwa JPC, et al. High SARS-CoV-2 Seroprevalence in Health care Workers in Bukavu, Eastern Democratic Republic of Congo. Am J
   Trop Med Hyg. 2021;104(4):1526–1530. doi:10.4269/ajtmh.20-1526.
- [14] Sykes W, Mhlanga L, Swanevelder R, Glatt TN, Grebe E, Coleman C,
   et al. Prevalence of anti-SARS-CoV-2 antibodies among blood donors in
   Northern Cape, KwaZulu-Natal, Eastern Cape, and Free State provinces
   of South Africa in January 2021. Res Sq. 2021;doi:10.21203/rs.3.rs 233375/v1.
- [15] United Nations, Department of Economic and Social Affairs, Popula tion Division. World urbanization prospects: the 2018 revision. United
   Nations; 2019. OCLC: 1120698127.
- [16] Prem K, van Zandvoort K, Klepac P, Eggo RM, Davies NG, Cook AR,
   et al. Projecting contact matrices in 177 geographical regions: an update

- and comparison with empirical data for the COVID-19 era. medRxiv. 585
- 2021;doi:https://doi.org/10.1101/2020.07.22.20159772. 586

595

- [17] COVAX Global Supply Forecast;. Available from: https://www.gavi. 587 org/news/document-library/covax-global-supply-forecast. 588
- [18] COVID-19 Platform:. Partners Available from: https: 580 //covid19partnersplatform.who.int/en/pillar10. 590
- vaccinating its poorest citizens first |19| Mexico is against the 591 health experts. advice of Washington Post. 2021; Available 592 https://www.washingtonpost.com/world/the\_americas/ from: 593 mexico-coronavirus-vaccine-lopez-obrador/2021/02/25/ 594 81c28c50-76ad-11eb-9537-496158cc5fd9\_story.html.
- [20] Ameyaw EK, Kareem YO, Ahinkorah BO, Seidu AA, Yaya S. Decom-596 posing the rural-urban gap in factors associated with childhood immu-597 nisation in sub-Saharan Africa: evidence from surveys in 23 countries. 598 BMJ Global Health. 2021 Jan;6(1):e003773. Available from: https:// 599 gh.bmj.com/content/6/1/e003773. doi:10.1136/bmjgh-2020-003773. 600
- [21] Matrajt L, Eaton J, Leung T, Brown ER. Vaccine optimization 601 for COVID-19: Who to vaccinate first? Sci Adv. 2020 Feb;7(6). 602 doi:10.1126/sciadv.abf1374. 603
- [22] COVAX Joint Statement: Call to action equip to 604 COVAX deliver 2 billion doses in 2021:. Avail-605 able from: https://www.who.int/news/item/ 606
- 27-05-2021-covax-joint-statement-call-to-action-to-equip-covax-to-deliver-2-1 607

```
[23] Communique of the High-Level Emergency Virtual Meeting of
                Ministers of Health On the COVID-19 situation
609
       Africa;.
                                    https://africacdc.org/news-item/
                   Available from:
       communique-of-the-high-level-emergency-virtual-meeting-of-african-ministers-of-
611
   [24] Civil society to World Bank:
                                        Help us hold governments ac-
       countable in COVID-19
                                vaccine distribution;
                                                        2021.
                                                                  Avail-
613
       able
                               https://www.devex.com/news/sponsored/
                from:
614
       civil-society-to-world-bank-help-us-hold-governments-accountable-in-covid-19-
615
   [25] Happi AN, Ugwu CA, Happi CT.
                                             Tracking the emergence of
616
       new SARS-CoV-2 variants in South Africa.
                                                       Nature Medicine.
617
       2021 Mar;27(3):372-373. Available from: https://www.nature.com/
       articles/s41591-021-01265-1. doi:10.1038/s41591-021-01265-1.
619
   [26] Happi C, Ihekweazu C, Oluniyi PE, Olawoye I. SARS-CoV-2 genomes
620
       from Nigeria reveal community transmission, multiple virus lineages
621
       and spike protein mutation associated with higher transmission and
622
       pathogenicity. 2020;. Available from: https://virological.org/t/
623
       sars-cov-2-genomes-from-nigeria-reveal-community-transmission-multiple-virus-
       494.
625
   [27] Githinji G. Introduction and local transmission of SARS-CoV-
626
       2 cases in Kenya;. Available from: https://virological.org/t/
627
       introduction-and-local-transmission-of-sars-cov-2-cases-in-kenya/
628
```

[28] Sabino EC, Buss LF, Carvalho MPS, Prete CA, Crispim MAE,

497.

629


- Fraiji NA, et al. Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. The Lancet. 2021 Feb;397(10273):452–455. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00183-5/abstract. doi:10.1016/S0140-6736(21)00183-5.
- 636 [29] COVID-19 Vaccination;. Available from: https://africacdc.org/ 637 covid-19-vaccination/.
- [30] Hale T, Webster S, Petherick A, Phillips T, Kira B. Oxford COVID19 Government Response Tracker. Blavatnik School of Government; 2020. Available from: https://www.bsg.ox.ac.uk/research/
  research-projects/covid-19-government-response-tracker.
- [31] Grantz KH, Meredith HR, Cummings DAT, Metcalf CJE, Grenfell BT, Giles JR, et al. The use of mobile phone data to inform analysis of COVID-19 pandemic epidemiology. Nat Commun. 2020 Sep 30;11(1):4961. doi:10.1038/s41467-020-18190-5.
- hart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19
  Vaccine. New England Journal of Medicine. 2020 Dec;383(27):2603–
  2615. Available from: https://doi.org/10.1056/NEJMoa2034577.
  doi:10.1056/NEJMoa2034577.
- [33] Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak
   R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2
   Vaccine. New England Journal of Medicine. 2021 Feb;384(5):403-


- 416. Available from: https://doi.org/10.1056/NEJMoa2035389.
  doi:10.1056/NEJMoa2035389.
- [34] Bershteyn A, Gerardin J, Bridenbecker D, Lorton CW, Bloedow J, Baker
   RS, et al. Implementation and applications of EMOD, an individual based multi-disease modeling platform. Pathog Dis. 2018;76(5):fty059.
   doi:10.1093/femspd/fty059.
- 660 [35] About Africa; 2021. Available from: https://www.africa.undp.org/ 661 content/rba/en/home/regioninfo.html.
- [36] World Population Prospects Population Division United Nations;
  2021. Available from: https://population.un.org/wpp/Download/
  Standard/Population/.
- [37] Ali ST, Wang L, Lau EHY, Xu XK, Du Z, Wu Y, et al. Serial interval of SARS-CoV-2 was shortened over time by nonpharmaceutical interventions. Science. 2020 Aug 28;369(6507):1106–1109.
   doi:10.1126/science.abc9004.
- 669 [38] WHO Coronavirus (COVID-19) Dashboard. Geneva: World Health Organization; 2021. Available from: https://covid19.who.int/info/.
- [39] Basta NE, Halloran ME, Matrajt L, Longini IM Jr. Estimating in fluenza vaccine efficacy from challenge and community-based study
   data. American Journal of Epidemiology. 2008 Dec;168(12):1343–1352.
   doi:10.1093/aje/kwn259.











16.0		7.0	5.0	3.0	2.0			20.0	16.0	11.0	8.0		1.0			26.0	19.0	14.0
		7.0	4.0	3.0	2.0	33.0			14.0	11.0	7.0	4	7.0			24.0	18.0	12.0
	7.0	6.0	4.0	3.0	2.0	30.0			14.0	10.0	6.0	4	4.0			23.0	17.0	11.0
	6.0	5.0	3.0	2.0	1.0	26.0			11.0	8.0	5.0					20.0	15.0	10.0
6.0	5.0	3.0	3.0	1.0	1.0	22.0		13.0	9.0	7.0	4.0	3			23.0	17.0	12.0	8.0
4.0	3.0	2.0	2.0	1.0	1.0	17.0	13.0	10.0	7.0	5.0	3.0	3		24.0	19.0	14.0	10.0	7.0
2.0	2.0	2.0	1.0	1.0	-0.0	12.0	10.0	7.0	5.0	4.0	2.0		2.0	19.0	14.0	11.0	8.0	5.0
4.0	4.0	2.0	2.0	2.0	1.0	33.0	27.0		15.0	11.0	7.0		1.0	42.0			20.0	13.0
4.0	3.0	2.0	2.0	1.0	1.0	30.0			14.0	10.0	6.0	1	0.8				18.0	12.0
3.0	2.0	2.0	1.0	1.0	1.0	28.0			12.0	9.0	6.0	4	7.0			23.0	17.0	11.0
																		10.0
2.0	2.0	1.0	1.0	1.0	1.0	23.0		14.0	11.0	8.0	5.0	4	0.0			20.0	15.0	10.0
1.0	2.0	1.0	1.0	1.0	1.0 -0.0	23.0	19.0 16.0	14.0	11.0 9.0	7.0	5.0 4.0		0.0	31.0	25.0	17.0	15.0	8.0
											2000	3						



